Re: Dr. Mark Day interview with Proactive Investors at BIO CEO
in response to
by
posted on
Feb 12, 2019 09:19AM
Bear Day states in the clip that the Xb3-001 with the antibody conjugate delivers consistently 4-6 % of the injected dose ( compared to the competition may deliver 1.5% max). The BBB being littered with Receptors so there are many doors to get to the BBB. The competition may use 10K to 100K to get to the BBB whereas BiOasis uses far fewer receptors less like 5K to get Xb3 to the BBB much faster. Do I have this correct?
You would think the more doors the better especially when 4-6% of the conjugate is being delivered as compared to only 1 to 1.5%.
Koo